Levetiracetam Treatment of Tardive Dyskinesia

This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Completed

Looking for future studies?

Key information

Conditions

Tardive Dyskinesia Central Nervous System Diseases Dyskinesia, Drug-Induced Dyskinesias Movement Disorders Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Connecticut Mental Health Center

New Haven, Connecticut, 06519, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

meet Glazer Morgenstern criteria for TD -

Exclusion criteria

none

Treatment and study plan

Levetiracetam

Drug

Placebo

Drug

Primary outcomes

Abnormal Involuntary Movement Scale (AIMS) Total Score

Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

UCB Pharma

Registry information

Important dates

Primary completion: 2006
First posted: Feb 13, 2006
Registry last updated: Jun 6, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed